Quality policy declaration

MEDITEST is ISO 9001: 2015 certified, on all the professions of its sales and services activities.
MEDITEST continues its development and strengthens its major actor positioning in the radiotherapy, radiology, nuclear medicine and research centers, for quality control solutions in medical imaging and precision medicine.

The field of application of the MEDITEST quality management system includes business and company sales and services activities, for the six processes, that is to say for the following functions:

• General Management
• The quality manager for activities for implementing, maintaining and improving the quality management system.
• The sales engineer and technical-commercial for the sale of equipment, consumables and maintenance contracts
• The maintenance technician for customer service, installation, user training and curative and preventive maintenance of equipment
• Assistants
• The command trainer.

MEDITEST does not implement design and development activities. As a result, the certification perimeter does not include these last two activities.
This is why the requirements of § 8.3 of the ISO 9001 V 2015 standard are not applicable within the framework of the field of application of its quality management system.
The raison d'être of MEDITEST is to help guarantee the quality diagnostic in medical imaging and the quality of treatment in radiotherapy, thanks to innovation, safety and performance requirements.
A CSR approach is being set up to optimize the environmental, social and economic impact of the company.
The sales and services activities of all of its products are developed with internationally renowned equipment. Since 2020, MEDITEST has strengthened its position on the radiotherapy market with IBA Dosimetry equipment. IBA Dosimetry innovates in radiotherapy and proton therapy, thanks to quality insurance solutions, independent and integrated which are effective, intuitive and which ensure the peace of mind of health professionals and patients around the world.

The guidelines of quality policy (in connection with the strategy) are:

• Refocus all employees on the culture and historical activity of the company: distribution in the French market for high added value equipment in the medical imaging and radiotherapy sector,
• Maintain the growth of sales and consumption equipment and services, in the radiotherapy, radiotiagnostic and nuclear medicine markets,
• Enrich the services of the customer service activity,
• Capitalize on the skills available in the company,
• Expand the portfolios produced consistent with precision medicine. These orientations are followed through objectives and indicators defined elsewhere, and revised regularly.

The quality system is based on all MEDITEST employees. It is led by two major functions: general management and quality manager.

The purpose of the quality management system is:

• To ensure the development and implementation of the management system
  for the continuous improvement of its effectiveness.
• To meet customer requirements as well as regulatory
  and legal requirements.

In order to meet the requirements of confidentiality and impartiality, the management of MEDITEST ensures that the services provided of the company are free of pressure or commercial, financial or other, internal or external influence, capable of questioning the quality of its work and that all the information related to all its activities is kept in all confidentiality. MEDITEST
management ensures through this declaration signed that these requirements are met. MEDITEST
activities must accept, from any origin whatsoever, pressures linked to assistance, preferential treatment, obstruction or delay in transactions between MEDITEST and its customers. Attempts at such pressures must be brought to the attention of the management of MEDITEST . Management must ensure that the appropriate actions are implemented, for example by replacing the personnel assigned to the file.

All information from sales and services are considered confidential. MEDITEST staff must preserve this confidentiality and process all information from the company as confidential.

BUC on 04/18/2023

______________
Bruno Torrès
Managing Director